Recent progress in mesenchymal stem cell-based therapy for acute lung injury

Jinfeng Liang; Weiyou Dai; Shihang Xue; Feifei Wu; Enhai Cui; Ruolang Pan

doi:10.1007/s10561-024-10129-0

Recent progress in mesenchymal stem cell-based therapy for acute lung injury

Cell Tissue Bank. 2024 Mar 11. doi: 10.1007/s10561-024-10129-0. Online ahead of print.

Authors

Jinfeng Liang¹, Weiyou Dai², Shihang Xue³, Feifei Wu^{4

5}, Enhai Cui⁶, Ruolang Pan^{7

8}

Affiliations

¹ Zhejiang Center for Drug and Cosmetic Evaluation, Hangzhou, China.
² School of Medicine, Zhejiang University, Hangzhou, China.
³ Xiangshan First People's Hospital Medical and Health Group, Ningbo, China.
⁴ Key Laboratory of Cell-Based Drug and Applied Technology Development in Zhejiang Province, Hangzhou, China.
⁵ Institute for Cell-Based Drug Development of Zhejiang Province, S-Evans Biosciences, No.181 Wuchang Road, Hangzhou, 311122, Zhejiang, People's Republic of China.
⁶ Huzhou Central Hospital, Zhejiang University Huzhou Hospital, Huzhou, 313000, People's Republic of China. kjkceh@126.com.
⁷ Key Laboratory of Cell-Based Drug and Applied Technology Development in Zhejiang Province, Hangzhou, China. panrl@zju.edu.cn.
⁸ Institute for Cell-Based Drug Development of Zhejiang Province, S-Evans Biosciences, No.181 Wuchang Road, Hangzhou, 311122, Zhejiang, People's Republic of China. panrl@zju.edu.cn.

PMID: 38466563
DOI: 10.1007/s10561-024-10129-0

Abstract

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are life-threatening diseases in critically ill patients. Although pathophysiology of ALI/ARDS has been investigated in many studies, effective therapeutic strategies are still limited. Mesenchymal stem cell (MSC)-based therapy is emerging as a promising therapeutic intervention for patients with ALI. During the last two decades, researchers have focused on the efficacy and mechanism of MSC application in ALI animal models. MSC derived from variant resources exhibited therapeutic effects in preclinical studies of ALI with different mechanisms. Based on this, clinical studies on MSC treatment in ALI/ARDS has been tried recently, especially in COVID-19 caused lung injury. Emerging clinical trials of MSCs in treating COVID-19-related conditions have been registered in past two years. The advantages and potential of MSCs in the defense against COVID-19-related ALI or ARDS have been confirmed. This review provides a brief overview of recent research progress in MSC-based therapies in preclinical study and clinical trials in ALI treatment, as well as the underlying mechanisms.

Keywords: Acute lung injury; Acute respiratory distress syndrome; Clinical trial; Mesenchymal stem/stromal cell; Research progress.

Publication types

Review